AGLE:NSD-Aeglea Bio Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 0.53

Change

+0.04 (+7.37)%

Market Cap

USD 0.03B

Volume

0.30M

Avg Analyst Target

USD 2.92 (+454.50%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


AGLE Stock Forecast & Price:
Based on the Aeglea Bio Therapeutics Inc stock forecasts from 5 analysts, the average analyst target price for Aeglea Bio Therapeutics Inc is USD 2.92 over the next 12 months. Aeglea Bio Therapeutics Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Aeglea Bio Therapeutics Inc is Bearish, which is based on 2 positive signals and 7 negative signals. At the last closing, Aeglea Bio Therapeutics Inc’s stock price was USD 0.53. Aeglea Bio Therapeutics Inc’s stock price has changed by +19.17% over the past week, +0.57% over the past month and -93.38% over the last year.

About Aeglea Bio Therapeutics Inc (AGLE:NSD)

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 tha ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-30 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

-2.95 (-0.43%)

USD76.14B 13.80 10.63
VRTX Vertex Pharmaceuticals Inc

-3.26 (-1.11%)

USD73.02B 23.28 15.15
MRNA Moderna Inc

+0.18 (+0.15%)

USD46.19B 3.66 2.45
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

+1.28 (+0.96%)

USD30.98B 2.87 1.32
RPRX Royalty Pharma Plc

-0.15 (-0.37%)

USD27.19B 39.06 19.32
SGEN Seagen Inc

+1.13 (+0.83%)

USD25.40B 55.02 -36.47
ALNY Alnylam Pharmaceuticals Inc

-9.23 (-4.41%)

USD25.13B N/A -31.40
GMAB Genmab AS

+0.20 (+0.63%)

USD21.66B 41.88 3.47
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing AGLE

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -88.93% 6% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -88.93% 6% F 5% F
Trailing 12 Months  
Capital Gain -93.59% 6% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -93.59% 6% F 4% F
Trailing 5 Years  
Capital Gain -89.33% 28% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -89.33% 28% F 9% F
Average Annual (5 Year Horizon)  
Capital Gain -11.38% 44% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.38% 44% F 22% F
Risk Return Profile  
Volatility (Standard Deviation) 43.88% 48% F 31% F
Risk Adjusted Return -25.94% 48% F 34% F
Market Capitalization 0.03B 24% F 16% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.33 95% A 95% A
Price / Cash Flow Ratio -0.60 20% F 46% F
EV/EBITDA 0.65 19% F 44% F
Management Effectiveness  
Return on Equity -86.14% 34% F 18% F
Return on Invested Capital -58.80% 44% F 22% F
Return on Assets -43.16% 23% F 9% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 0.16 95% A 90% A-
Short Percent 1.43% 69% D+ 60% D-
Beta 1.66 25% F 18% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector